Further studies of inhibitors targeting mutated effectors of EGFR and molecules further downstream may elucidate mechanisms by which HNSCC cells possess or acquire resistance to EGFR directed therapy. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.